Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer

Mariaelena Pierobon(George Mason University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Mohammad Jahanzeb(Florida Atlantic University), Julia Wulfkuhle(University of California, San Francisco), Linda Vocila(Translational Genomics Research Institute), Stephen P. Anthony, Massimo Cristofanilli(Cornell University), Joyce O’Shaughnessy(Baylor University Medical Center), Nicholas N Hoke(Theranostics (New Zealand)), Donald W. Northfelt(Mayo Clinic in Arizona), Rosa I. Gallagher(George Mason University), Brian Leyland‐Jones(Avera Health), David W. Craig(City of Hope), Nicholas J. Robert(Tufts Medical Center), Guido Gambara(George Mason University), John D. Carpten(City of Hope), Lance A. Liotta(George Mason University), Jessica Aldrich(Translational Genomics Research Institute), Ting Dong(China Three Gorges University), Shukmei Wong(Translational Genomics Research Institute), Corinne Ramos, Bryant Dunetz(Side-Out Foundation), K. Alex Hodge(George Mason University), Sara A. Byron(Translational Genomics Research Institute)
Unknown
March 31, 2023
10.1158/1078-0432.22462946
Cited by 0

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846